SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-23-033452
Filing Date
2023-09-22
Accepted
2023-09-22 16:05:47
Documents
55
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1143469
2 ex23-1.htm EX-23.1 3458
3 ex31-1.htm EX-31.1 12232
4 ex31-2.htm EX-31.2 12245
5 ex32-1.htm EX-32.1 6159
6 ex32-2.htm EX-32.2 6333
7 form10-k_010.jpg GRAPHIC 53771
  Complete submission text file 0001493152-23-033452.txt   3679314

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE aneb-20230630.xsd EX-101.SCH 26799
9 XBRL CALCULATION FILE aneb-20230630_cal.xml EX-101.CAL 29454
10 XBRL DEFINITION FILE aneb-20230630_def.xml EX-101.DEF 65424
11 XBRL LABEL FILE aneb-20230630_lab.xml EX-101.LAB 206518
12 XBRL PRESENTATION FILE aneb-20230630_pre.xml EX-101.PRE 155260
49 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 303157
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-K | Act: 34 | File No.: 001-40388 | Film No.: 231271758
SIC: 2834 Pharmaceutical Preparations